Beyond Air Inc.

Solid Tumors

Beyond Air has developed a proprietary system for the administration of nitric oxide at ultra-high concentrations directly to solid tumors. Please see our e-poster “Gaseous Nitric Oxide at high concentration is a powerful anti-tumor agent both in-vitro and in-vivo” here, presented at the American Association for Cancer Research Virtual Annual Meeting II on June 22nd 2020. You can listen to the accompanying audio file here.

Product Status and Market Potential

Beyond Air Pipeline & Market Size

Product Indication Development
Status		 Key Dates* US Sales
Potential**		 Worldwide Sales
Potential**
Solid Tumors Multiple solid tumors Pre-clinical New in vivo data
to be presented 4Q20		 TBD TBD

Nitri*All dates are based on projections and appropriate financing, anticipated first launch on global basis pending appropriate regulatory approvals

**All figures are Company estimates for peak year sales: Global Sales Potential includes US Sales Potential

Resources to Learn More

Important Safety Information

†Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.